

Company name: Mitsubishi Tanabe Pharma Corporation

Representative: Masayuki Mitsuka

President and Representative Director

Code number: 4508, First Section, Tokyo Stock Exchange

Contact: Yoshiaki Takai, Vice President,

Head of Corporate Communications Department

(TEL: +81-6-6205-5211)

Announcement Concerning Delisting of the Company Shares

Mitsubishi Tanabe Pharma Corporation (the "Company") resolved to approve the demand for the sale of the stock of the Company (the "Company Shares") made by Mitsubishi Chemical Holdings Corporation, which is the Company's special controlling shareholder at the Company's board of directors meeting held on January 17, 2020. The Company therefore announces that the Company Shares met the stock delisting criteria of the Tokyo Stock Exchange upon this approval and the Company will be delisted on February 27, 2020.

For details, please refer to "Announcement of Mitsubishi Chemical Holdings Corporation's Decision to Make a Demand for Sale of Our Shares, and Our Approval of that Demand for Sale of Our Shares and Delisting of Our Shares" released by the Company on January 17, 2020.

The Company expresses its sincere gratitude to shareholders and other stakeholders for their understanding and wholehearted support of the Company's management for many years since the Company was listed.

The Company will contribute to the healthier lives of people around the world as a member of Mitsubishi Chemical Holdings Group, and kindly asks for your continued support and cooperation.

-End-